Patent · US Active

Compositions and methods for TCR reprogramming using fusion proteins

US11085021B2 · kind B2 · utility

1Cited by

62References

27Claims

0Family size

Assignee

TCR2 THERAPEUTICS INC. · US

Inventors

Patrick Baeuerle · Gauting, DE
Gregory Sieczkiewicz · Wellesley, US
Robert Hofmeister · Scituate, US
Holger Wesche · San Francisco, US
Bryan D. LEMON · Mountain View, US
Richard J. Austin · Windsor, GB
Robert B. Dubridge · Belmont, US

Key dates

Filing date	Aug 10, 2020
Grant date	Aug 10, 2021
Priority date	—
Expiry date	Aug 10, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.